Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Eli Lilly shares rose in extended-hours trading on Monday after a panel of independent ...
Eli Lilly's stock has seen significant gains due to the success of its GLP-1 franchise and the potential of donanemab for Alzheimer's disease. The FDA's Advisory Committee endorsed donanemab for ...
June 10 (Reuters) - Outside advisers to the U.S. Food and Drug Administration on Monday voted unanimously that the benefits of Eli Lilly's (LLY.N) , opens new tab experimental Alzheimer's ...
Eli Lilly and Company announced that Anat Ashkenazi has decided to step down as chief financial officer. 1 She will continue to serve in the role through July 2024, at which point she will pursue a ...
A highly anticipated Alzheimer’s medication from Eli Lilly gained the support of a federal advisory panel Monday, paving the way for it to become the second drug of its kind authorized in the ...
, opens new tab late stage trial on experimental obesity pill orforglipron is expected in April 2025, a top Eli Lilly (LLY.N) , opens new tab executive said on Monday. The pill is part of a class ...
Glencar has taken over the construction of a life sciences building near Cambridge from collapsed contractor Readie. Readie ...
As Google (GOOG, GOOGL) pivots to incorporate AI technology across its array of services, its parent company, Alphabet, is bringing on a new CFO. Anat Ashkenazi, a 23-year veteran of the ...
A federal advisory panel on Monday voted in favor of recommending Eli Lilly’s new drug that is under consideration for its potential to slow the progression of Alzheimer’s disease. The Food ...
A Food and Drug Administration advisory panel on Monday endorsed the experimental Alzheimer's drug donanemab, which studies showed slowed early stages of the fatal mind-robbing disease. The ...